Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

An Investigation of Electrical Stimulation on Gastroesophageal Reflux Disease (GERD) in Patients After Sleeve Gastrectomy

6 augustus 2014 bijgewerkt door: Maastricht University Medical Center

Sleeve gastrectomy (SG) has gained popularity as both a staged and a definitive procedure for morbid obesity due to its technical simplicity, low-morbidity and excellent results both for weight loss and control of metabolic syndrome. There are however reports of SG worsening pre-existing GERD or causing new-onset GERD. Because of this, patients with pre-existing GERD have been denied the benefits of SG. In addition, patients that develop post-op GERD cannot undergo traditional anti-reflux surgery since the gastric fundus that is required for fundoplication is removed during the SG. Hence, patients with post-SG GERD not adequately controlled with medication can only opt for the more invasive gastric bypass procedure as their only surgical treatment option.

In a recently reported case study, an obese patient with severe GERD successfully treated with EndoStim underwent SG and maintained adequate GERD control with continued use of LES stimulation therapy. However electrical stimulation was not yet tested systematically in patients with prior gastric operation such as sleeve gastrectomy.

This study will test the hypothesis that electrical stimulation is effective in control of GERD associated with SG.

Studie Overzicht

Toestand

Onbekend

Conditie

Interventie / Behandeling

Studietype

Ingrijpend

Inschrijving (Verwacht)

10

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

  • Nederland
      • Maastricht, Nederland, 6229 HX
        • Werving
        • Maastricht University Medical Center
        • Contact:
        • Hoofdonderzoeker:
          • Nicole D. Bouvy, MD PhD
        • Onderonderzoeker:
          • José M Conchillo, MD PhD
        • Onderonderzoeker:
          • Nicolaas F. Rinsma, MD
        • Onderonderzoeker:
          • Selwyn Van Rijn, MD

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar tot 80 jaar (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  1. Subject is between 18 - 80 years of age.
  2. Subject underwent a sleeve gastrectomy minimum one year prior to enrollment (in order to have reached a stable weight loss plateau).
  3. Subject has a history of heartburn, regurgitation or both for >6 month prompting physician recommendation of continual daily use of PPI after sleeve gastrectomy.
  4. Baseline off-PPI GERD-HRQL score ≥ 20 following 10-14 days off PPI
  5. Baseline off-PPI GERD-HRQLscore is at least 5 points higher than the on-PPI score or a positive relationship between the occurrence of their primary symptom during the pH impedance monitoring (symptom association probability ≥ 95% or a SI score ≥ 50%) is present.
  6. Subject who are on standard medical therapy for 6 months or longer and experience discomfort or who are otherwise dissatisfied with GERD symptoms.
  7. Subjects with a GERD condition that in the opinion of the PI justifies a minimally invasive reversible procedure prior to attempting a more drastic procedure such as a gastric bypass.
  8. Subject has exhibited excessive lower esophageal acid exposure during 24-hour pH-metry of antisecretory therapy performed within 6 months of screening visit; pH < 4 for > 6% of total time.
  9. Subject has a resting LES end expiratory pressure ≥ 5mmHg on manometry performed within 6 months of enrollment.
  10. Subject has no esophagitis or esophagitis ≤ Grade C (LA classification) on upper endoscopy within 6 months of enrollment.
  11. Subject has esophageal body contraction amplitude > 30 mmHg for >30% of swallows and > 30% peristaltic contractions on manometry.
  12. Subject has signed the informed consent form and is able to adhere to study visit schedule.

Exclusion Criteria:

  1. Subject has any non-GERD esophageal motility disorders.
  2. Subject has evidence of obstruction or stricture in the gastric sleeve by a barium swallow and endoscopy.
  3. Subject has any significant multisystem diseases.
  4. Subject has an autoimmune or a connective tissue disorder (e.g. scleroderma, dematomyositis, Calcinosis-Raynaud's-Esophagus Sclerodactyly Syndrome (CREST), Sjogren's Syndrome, Sharp's Syndrome) requiring therapy in the preceding 2 years.
  5. Subject has Barrett's epithelium (> M2; >C1) or any grade of dysplasia.
  6. Subject has a hiatal hernia larger than 3 cm.
  7. Subject has a body mass index (BMI) greater than 35 kg/m2.
  8. Subject has Type 1 Diabetes Mellitus
  9. Subject has uncontrolled Type 2 Diabetes Mellitus (T2DM) defined as HbA1c >9.5 in the previous 6 months, or has T2DM for > 10 years.
  10. Subject has a history of suspected or confirmed esophageal or gastric cancer.
  11. Subject has esophageal or gastric varices.
  12. Subject has significant cardiac arrhythmia or ectopy or significant cardiovascular disease.
  13. Subject has an existing implanted electrical stimulator (e.g., pacemaker, AICD).
  14. Subject requires chronic anticoagulant therapy.
  15. Subject has dysphagia or esophageal peptic stricture, excluding Schatzki's ring.
  16. Subject of child-bearing potential who is pregnant or intends to become pregnant during the trial period.
  17. Subject is currently enrolled in other potentially confounding research.
  18. History of any malignancy in the last 2 years.
  19. Subject has any condition that, at the discretion of the investigator, would preclude participation in the trial.
  20. Weight change of +/- 10% of the EWL (Excess Weight Loss) in the 3 months prior to enrollment.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Niet-gerandomiseerd
  • Interventioneel model: Opdracht voor een enkele groep
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Electrical Stimulation Therapy
Apparaat: LES-Stimulation Device
Andere namen:
  • EndoStim b.v.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
The incidence and severity of any complications that are associated with the investigational stimulation device throughout the follow-up period.
Tijdsspanne: up to 12 month follow-up
up to 12 month follow-up
Efficacy - Disease specific quality of life
Tijdsspanne: Baseline, 6 and 12 month follow up
The change in patient's GERD-HRQL, where applicable, from baseline (as measured while off PPI) .
Baseline, 6 and 12 month follow up

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
pH-monitoring
Tijdsspanne: Baseline, 6 and 12 month FU
The change in baseline pH values of % 24-hour esophageal pH< 4.0 and number of reflux events >1minute and >5 minute duration with the same on-stimulation pH parameters at 6 months and at 12 months.
Baseline, 6 and 12 month FU
Questionnairres, symptom diary
Tijdsspanne: baseline, 6 and 12 month FU
Change in symptoms frequency and severity at 6 months vs. baseline and at 12 months vs. baseline as measured by patient symptom diary, structured GI questionnaire, and patients quality of life measured by SF-12.
baseline, 6 and 12 month FU
Anti-secretory medication use
Tijdsspanne: Baseline, 6 and 12 month FU
Change in anti-secretory medication use as evaluated during the two weeks prior to the 6 mo and 12 mo follow up compared to baseline.
Baseline, 6 and 12 month FU
HR-manometry
Tijdsspanne: Baseline, 6 and 12 month FU
Change in LES end expiratory pressure (LESPpre) and the on-stimulation LES end expiratory pressure (LESPpost) at 6 months and 12 months in mmHg.
Baseline, 6 and 12 month FU

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Maastricht University Medical Center

Medewerkers

EndoStim Inc.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start

1 juli 2014

Primaire voltooiing (Verwacht)

1 januari 2016

Studie voltooiing (Verwacht)

1 februari 2016

Studieregistratiedata

Eerst ingediend

4 augustus 2014

Eerst ingediend dat voldeed aan de QC-criteria

6 augustus 2014

Eerst geplaatst (Schatting)

7 augustus 2014

Updates van studierecords

Laatste update geplaatst (Schatting)

7 augustus 2014

Laatste update ingediend die voldeed aan QC-criteria

6 augustus 2014

Laatst geverifieerd

1 augustus 2014

Meer informatie

Termen gerelateerd aan deze studie

Trefwoorden

Aanvullende relevante MeSH-voorwaarden

Andere studie-ID-nummers

  • NL4834906814

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren